Axovant Sciences Ltd. (NYSE:AXON) Posts Earnings Results, Misses Estimates By $0.12 EPS
Axovant Sciences Ltd. (NYSE:AXON) announced its earnings results on Monday. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.12, MarketWatch Earnings reports.
Shares of Axovant Sciences (AXON) traded down 2.36% during midday trading on Tuesday, reaching $22.35. The company had a trading volume of 354,533 shares. The company has a 50 day moving average price of $22.85 and a 200-day moving average price of $18.65. Axovant Sciences has a one year low of $11.01 and a one year high of $26.49. The firm’s market capitalization is $2.40 billion.
A number of brokerages have recently weighed in on AXON. BidaskClub upgraded Axovant Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, August 3rd. Jefferies Group LLC reiterated a “buy” rating and set a $31.00 target price on shares of Axovant Sciences in a research note on Friday, June 9th. Oppenheimer Holdings, Inc. increased their target price on Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 14th. Cowen and Company reiterated an “outperform” rating and set a $30.00 target price (up previously from $22.00) on shares of Axovant Sciences in a research note on Tuesday, June 13th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $32.00 target price on shares of Axovant Sciences in a research note on Wednesday, April 12th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $28.50.
ILLEGAL ACTIVITY WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/08/axovant-sciences-ltd-nyseaxon-posts-earnings-results-misses-estimates-by-0-12-eps.html.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.